What is it about?
When oxaliplatin has been combined with anti-EGFR therapies, a detrimental effect has been observed in KRAS mutated patients. Even for wild-type patients, anti-EGFRs seem not to be the best partner for oxaliplatin. In this paper we describe our hypothesis concerning this supposed negative interference.
Featured Image
Why is it important?
This paper, with an original point of view, gives reason both of detrimental effect observed in KRAS mutated and also of the puzzling results observed when oxaliplatin has been combined with anti-EGFR therapies even in wild type RAS patients. Moreover our point of view seems to be able to explain some particular issues, such as the detrimental effect observed in the microscopic disease of wild-type patients.
Perspectives
The hypothesis we propose in this paper, if confirmed, wil offer the possibility of further personalized therapies in patients affected by advanced colorectal cancer, based on the rate of membrane EGFR expression.
Michele Basso
Fondazione Policlinico Universitario "A Gemelli" IRCCS
Read the Original
This page is a summary of: The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the ‘unexplainable’, Personalized Medicine, July 2018, Future Medicine,
DOI: 10.2217/pme-2017-0082.
You can read the full text:
Contributors
The following have contributed to this page
